CL2016002640A1 - Procedimiento de preparación y formas cristalinas de los enantiómeros ópticos de modafinilo (divisional solicitud de origen 2693-2003). - Google Patents

Procedimiento de preparación y formas cristalinas de los enantiómeros ópticos de modafinilo (divisional solicitud de origen 2693-2003).

Info

Publication number
CL2016002640A1
CL2016002640A1 CL2016002640A CL2016002640A CL2016002640A1 CL 2016002640 A1 CL2016002640 A1 CL 2016002640A1 CL 2016002640 A CL2016002640 A CL 2016002640A CL 2016002640 A CL2016002640 A CL 2016002640A CL 2016002640 A1 CL2016002640 A1 CL 2016002640A1
Authority
CL
Chile
Prior art keywords
origin
divisional application
crystalline forms
preparation procedure
optical enantiomers
Prior art date
Application number
CL2016002640A
Other languages
English (en)
Inventor
Oliver Neckebrock
Laurent Courvoisier
Stéphanie Graf
Gilles Serrure
Gerard Coquerel
Sébastien Rose
Christine Besselievre
Franck Mallet
Langevelde Adriaan Jan Van
Original Assignee
Teva Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32406320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002640(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Sante filed Critical Teva Sante
Publication of CL2016002640A1 publication Critical patent/CL2016002640A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PROCEDIMIENTO DE PREPARACIÓN DE MODAFINILO ÓPTICAMENTE ACTIVO A PARTIR DEL ÁCIDO MODAFÍNICO (DIV. SOL. 2693-2003).
CL2016002640A 2002-12-20 2016-10-17 Procedimiento de preparación y formas cristalinas de los enantiómeros ópticos de modafinilo (divisional solicitud de origen 2693-2003). CL2016002640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0216412A FR2849029B1 (fr) 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.

Publications (1)

Publication Number Publication Date
CL2016002640A1 true CL2016002640A1 (es) 2017-03-24

Family

ID=32406320

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2007002450A CL2007002450A1 (es) 2002-12-20 2007-08-22 Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).
CL2016002640A CL2016002640A1 (es) 2002-12-20 2016-10-17 Procedimiento de preparación y formas cristalinas de los enantiómeros ópticos de modafinilo (divisional solicitud de origen 2693-2003).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2007002450A CL2007002450A1 (es) 2002-12-20 2007-08-22 Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).

Country Status (30)

Country Link
US (10) US7132570B2 (es)
EP (6) EP2679578B1 (es)
JP (2) JP4719471B2 (es)
KR (1) KR101050565B1 (es)
CN (5) CN106065007A (es)
AR (1) AR042546A1 (es)
AU (2) AU2003299349C1 (es)
BR (1) BRPI0316916B1 (es)
CA (2) CA2510096C (es)
CL (2) CL2007002450A1 (es)
CY (1) CY1114291T1 (es)
DK (1) DK2343275T3 (es)
EA (1) EA009592B1 (es)
EG (1) EG24849A (es)
ES (3) ES2627808T3 (es)
FR (1) FR2849029B1 (es)
HK (1) HK1225371A1 (es)
IL (1) IL169205A (es)
IS (1) IS7947A (es)
MX (1) MXPA05006525A (es)
MY (1) MY142926A (es)
NO (1) NO335724B1 (es)
NZ (2) NZ540733A (es)
PL (1) PL377196A1 (es)
PT (1) PT2343275E (es)
SI (1) SI2343275T1 (es)
TW (1) TWI344952B (es)
UA (1) UA100964C2 (es)
WO (1) WO2004060858A1 (es)
ZA (1) ZA200504805B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003074474A2 (en) 2002-03-01 2003-09-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20050025791A1 (en) 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
WO2004082630A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
EP1603889A1 (en) 2003-03-17 2005-12-14 Hetero Drugs Limited Novel crystalline forms of lamotrigine
JP4842819B2 (ja) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド モダフィニル組成物
EP1516869A1 (en) 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20090018202A1 (en) 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP1718607A4 (en) * 2004-02-06 2008-05-28 Cephalon Inc COMPOSITIONS BASED ON MODAFINIL
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
US20060086667A1 (en) * 2004-09-13 2006-04-27 Cephalon, Inc., U.S. Corporation Methods for the separation of enantiomeric sulfinylacetamides
EP1702915A1 (en) * 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
US20090123545A1 (en) * 2005-07-21 2009-05-14 Ron Eyal S Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
JP2009508880A (ja) * 2006-02-21 2009-03-05 テバ ファーマシューティカル インダストリーズ リミティド アルモダフィニルの新規な結晶形とその調製方法
WO2007103221A2 (en) * 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
MX2009000391A (es) * 2006-07-12 2009-06-30 Elan Pharma Int Ltd Formulación de modafinilo en forma de nano-partículas.
CA2660565C (en) * 2006-08-14 2012-10-09 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080214862A1 (en) * 2006-12-06 2008-09-04 Ben-Zion Dolitzky Processes for preparing armodafinil intermediate
CN101641090B (zh) * 2006-12-19 2012-12-05 亚勒斯有限公司 莫达非尼在制备治疗多动腿综合征的药物中的应用
AU2008259588A1 (en) * 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
WO2009024863A2 (en) * 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
US7960586B2 (en) 2007-08-16 2011-06-14 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
WO2009090663A1 (en) * 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2292306B1 (en) 2009-09-02 2013-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device
WO2011061610A2 (en) * 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
US20110224196A1 (en) * 2010-01-07 2011-09-15 Vivus, Inc. Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
HUE037616T2 (hu) 2010-12-08 2018-09-28 Codexis Inc Biokatalizátorok és eljárások armodafinil szintéziséhez
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
US10466776B2 (en) * 2014-06-24 2019-11-05 Paypal, Inc. Surfacing related content based on user interaction with currently presented content
WO2016012865A2 (en) * 2014-07-23 2016-01-28 Yonatan Wexler Wearable apparatus and methods for processing image data
KR20180123194A (ko) * 2014-11-27 2018-11-14 가부시키가이샤 지씨 왁스 패턴용 표면처리제 및 치과용 보철물을 제조하기 위한 방법
WO2017064723A1 (en) * 2015-10-12 2017-04-20 Natco Pharma Ltd An improved process for the preparation of armodafinil

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
GB1197809A (en) 1968-02-13 1970-07-08 Inst Noguchi Method for Continuous Optical Resolution of Organic Racemates.
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr) 1986-04-28 1990-11-16 Lafon Labor Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
FR2626881B1 (fr) 1988-02-10 1990-07-27 Lafon Labor 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2671349B1 (fr) 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
FR2710337B1 (fr) * 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
CN1249932A (zh) 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
SK9742002A3 (en) 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US20010036640A1 (en) 2000-04-25 2001-11-01 D'amico Kevin L. System and methods for the high throughput screening of polymorphs
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
DE10025756C2 (de) * 2000-05-25 2003-02-20 Cognis Deutschland Gmbh Lösungsvermittler
DK1787980T3 (da) * 2000-07-27 2010-04-26 Teva Pharma Krystallint og rent modafinil og fremgangsmåde til atfremstille dette
US6835307B2 (en) * 2000-08-04 2004-12-28 Battelle Memorial Institute Thermal water treatment
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6919378B2 (en) 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
CZ20031495A3 (cs) 2000-11-03 2004-01-14 Teva Pharmaceutical Industries Ltd. Forma VII hemi-kalcium atorvastatinu
IL158959A (en) 2001-05-25 2010-06-30 Cephalon Inc Solid pharmaceutical formulations comprising modafinil
EP1425577A4 (en) 2001-08-10 2004-12-29 Symyx Technologies Inc APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS
WO2003060497A1 (en) 2002-01-15 2003-07-24 Avantium International B.V. Method for performing powder diffraction analysis
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US7229644B2 (en) 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
ATE366137T1 (de) 2002-08-02 2007-07-15 Avantium Int Bv Vorrichtung und verfahren zur parallelen durchführung chemischer experimente, insbesondere kristallisationsexperimente
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
EP1567497B1 (en) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
AU2004270238B2 (en) 2003-09-04 2010-07-29 Cephalon, Inc. Modafinil compositions
US7566805B2 (en) * 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
EP1718607A4 (en) 2004-02-06 2008-05-28 Cephalon Inc COMPOSITIONS BASED ON MODAFINIL
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
CA2584246C (en) 2004-10-13 2011-08-09 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
US20090123545A1 (en) * 2005-07-21 2009-05-14 Ron Eyal S Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
JP2009508880A (ja) 2006-02-21 2009-03-05 テバ ファーマシューティカル インダストリーズ リミティド アルモダフィニルの新規な結晶形とその調製方法
WO2007103221A2 (en) 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
AU2008259588A1 (en) 2007-06-04 2008-12-11 Generics [Uk] Limited Novel process
WO2009024863A2 (en) 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
US7960586B2 (en) 2007-08-16 2011-06-14 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
EP1911739A3 (en) * 2007-11-05 2008-09-17 Dipharma Francis S.r.l. Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate
WO2009090663A1 (en) 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof

Also Published As

Publication number Publication date
EP2343275B1 (fr) 2013-04-24
CN100540533C (zh) 2009-09-16
FR2849029A1 (fr) 2004-06-25
CN1751021A (zh) 2006-03-22
US20100048718A1 (en) 2010-02-25
EP2679576A2 (fr) 2014-01-01
US9382200B2 (en) 2016-07-05
US20060241320A1 (en) 2006-10-26
US8975442B2 (en) 2015-03-10
BR0316916A (pt) 2005-10-18
HK1192222A1 (zh) 2014-08-15
IL169205A (en) 2013-11-28
IS7947A (is) 2005-07-19
CN101654423A (zh) 2010-02-24
US20100048719A1 (en) 2010-02-25
EP1572635A1 (fr) 2005-09-14
JP2006511588A (ja) 2006-04-06
ZA200504805B (en) 2006-07-26
EA009592B1 (ru) 2008-02-28
DK2343275T3 (da) 2013-07-01
TWI344952B (en) 2011-07-11
NZ540733A (en) 2008-10-31
US20100022653A1 (en) 2010-01-28
US20140031589A1 (en) 2014-01-30
NO20052912L (no) 2005-07-19
JP2011102330A (ja) 2011-05-26
KR20050085847A (ko) 2005-08-29
JP5497680B2 (ja) 2014-05-21
BRPI0316916B1 (pt) 2021-11-30
US20090281193A1 (en) 2009-11-12
NZ571235A (en) 2010-01-29
CA2724305A1 (fr) 2004-07-22
TW200419175A (en) 2004-10-01
BRPI0316916A8 (pt) 2015-09-22
US20100048720A1 (en) 2010-02-25
AU2010212462A1 (en) 2010-09-16
EP2679577A3 (fr) 2014-02-12
CN101012189A (zh) 2007-08-08
US20090281192A1 (en) 2009-11-12
CA2510096C (fr) 2011-02-22
UA100964C2 (ru) 2013-02-25
CN101914044A (zh) 2010-12-15
US20060135621A1 (en) 2006-06-22
EP1572635B1 (fr) 2017-04-12
FR2849029B1 (fr) 2005-03-18
CN106065007A (zh) 2016-11-02
EP2679576A3 (fr) 2014-02-12
AU2003299349A1 (en) 2004-07-29
PT2343275E (pt) 2013-07-30
EP2343275A2 (fr) 2011-07-13
EP2679578A3 (fr) 2014-03-19
ES2627808T3 (es) 2017-07-31
EP2679578A2 (fr) 2014-01-01
EP2343275A3 (fr) 2011-08-17
AU2003299349A8 (en) 2004-07-29
MXPA05006525A (es) 2005-12-05
WO2004060858A1 (fr) 2004-07-22
ES2575018T3 (es) 2016-06-23
EA200501016A1 (ru) 2005-12-29
AR042546A1 (es) 2005-06-22
EP2679578B1 (fr) 2016-03-09
CL2007002450A1 (es) 2009-01-16
CN101012189B (zh) 2013-03-13
CY1114291T1 (el) 2016-08-31
KR101050565B1 (ko) 2011-07-19
CA2510096A1 (fr) 2004-07-22
SI2343275T1 (sl) 2013-10-30
PL377196A1 (pl) 2006-01-23
HK1225371A1 (zh) 2017-09-08
US20130274521A1 (en) 2013-10-17
MY142926A (en) 2011-01-31
EP2676952A2 (fr) 2013-12-25
JP4719471B2 (ja) 2011-07-06
ES2425023T3 (es) 2013-10-10
EP2679577A2 (fr) 2014-01-01
US7132570B2 (en) 2006-11-07
AU2003299349B2 (en) 2010-06-03
US8729305B2 (en) 2014-05-20
NO335724B1 (no) 2015-02-02
EG24849A (en) 2010-10-27
EP2676952A3 (fr) 2014-02-12
NO20052912D0 (no) 2005-06-15
AU2003299349C1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
DE60239592D1 (de) Optische aufheller, deren herstellung und verwendung
BR0209984A (pt) Processo para a preparação de prostaglandinas e seus análogos
EA200702346A1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ЕЁ ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ
CY1113362T1 (el) Διαρυλ-αιθερες, ως ανταγωνιστης οπιοειδους υποδοχεως
BR0207270A (pt) Compostos de triazol como inibidores de mmp
ATE520674T1 (de) Natriumkanalblocker
UY27304A1 (es) Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
DK1406876T3 (da) 2-anilinopyrimidinderivater som inhibitorer af cyclinafhængige kinaser
CY1114291T1 (el) Κρυσταλλικη μορφη των οπτικων εναντιομερων της μοδαφινιλης
CO5590895A2 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos
BRPI0611350B8 (pt) formulação, seus usos e seu processo de fabricação,e artigo de fabricação
UY28127A1 (es) Nuevos enantiomeros (r) y (s) de derivados del acido tiofeno hidroxamico
NO20034660D0 (no) Spiropyrazolforbindelser
DK1608309T3 (da) 10,10-Dialkylprostanoidsyrederivater som midler til reduktion af det intraokulare tryk
MXPA03011954A (es) Nuevos derivados de acido sulfonico.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
BR0209695A (pt) Conjugados de lipìdeo-polìmero
NO20053099L (no) Fremgangsmate for a fremstille optisk rene aktive forbindelser
AR050518A1 (es) Proceso de amonolisis para la preparacion de intermedarios para inhibidores de dpp iv
NO20040388L (no) Fremgangsmåte for fremstilling av beraprost og salter derav, samt forbindelser som er mellomprodukter i fremgangsmåten
DK1427286T3 (da) Fremgangsmåde til udtynding af frugt
UY27632A1 (es) Metabolitos del ácido (3-((4- terc- butilbencil)-piridin.3- sulfonil) amino) metil ) fenoxi) acético
NO20050667L (no) N-substituerte-1H-indol-5-propionsyreforbindelser som PPAR agonister nyttige for behandling av diabetes
NO20060379L (no) Den polymorfe form av 4-[6-acetyl-3-[3-(4-acetyl-3-hydroksy-2-propylfenyltio)propoksy]-2-propylfenoksybutansyre
EA200600898A1 (ru) Новый способ синтеза периндоприла и его фармацевтически приемлемых солей